Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Florian Lasch, Lorenzo Guizzaro, Frank Pétavy & Ciro Gallo. (2023) A Simulation Study on the Estimation of the Effect in the Hypothetical Scenario of No Use of Symptomatic Treatment in Trials for Disease-Modifying Agents for Alzheimer’s Disease. Statistics in Biopharmaceutical Research 15:2, pages 386-399.
Read now
Read now
Xinnan Zhang, Yan Wu, Yao He, Xiaoyan Ge, Jing Cui, Hongjuan Han, Yanhong Luo, Long Liu, Zhixin Wang & Hongmei Yu. (2022) Metrological properties of neuropsychological tests for measuring cognitive change in individuals with prodromal Alzheimer’s disease. Aging & Mental Health 26:10, pages 1988-1996.
Read now
Read now
Anders Gustavsson, Peter Pemberton-Ross, Melissa Gomez Montero, Mahmoud Hashim & Robin Thompson. (2020) Challenges in demonstrating the value of disease-modifying therapies for Alzheimer’s disease. Expert Review of Pharmacoeconomics & Outcomes Research 20:6, pages 563-570.
Read now
Read now
Jill Rasmussen. (2019) The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer’s disease?. Clinical Interventions in Aging 14, pages 1481-1492.
Read now
Read now
Articles from other publishers (37)
Ivelina Gueorguieva, Laiyi Chua, Brian A. Willis, John R. Sims & Alette M. Wessels. (2022) Disease progression model using the integrated Alzheimer's Disease Rating Scale. Alzheimer's & Dementia 19:6, pages 2253-2264.
Crossref
Crossref
Samira Jamalian, Michael Dolton, Pascal Chanu, Vidya Ramakrishnan, Yesenia Franco, Kristin Wildsmith, Paul Manser, Edmond Teng, Jin Y. Jin, Angelica Quartino & Joy C. Hsu. (2023) Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR‐SB. CPT: Pharmacometrics & Systems Pharmacology.
Crossref
Crossref
Emma Nichols, Derek K Ng, Bryan D James, Jennifer A Deal & Alden L Gross. (2023) Measurement of Prevalent Versus Incident Dementia Cases in Epidemiologic Studies. American Journal of Epidemiology 192:4, pages 520-534.
Crossref
Crossref
J. Scott Andrews, Urvi Desai, Noam Y. Kirson & Brandy R. Matthews. (2023) Response to van Dyck, O'Dell, & Mecca letter to the editor regarding Andrews et al. (2019). Alzheimer's & Dementia: Translational Research & Clinical Interventions 9:2.
Crossref
Crossref
Kumar Kandadi Muralidharan, Kenneth G. Kowalski, Xiao Tong, Samantha Budd Haeberlein, Rajasimhan Rajagovindan & Ivan Nestorov. (2023) Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials. Journal of Pharmacokinetics and Pharmacodynamics 50:1, pages 45-62.
Crossref
Crossref
Pei-Hao Chen, Ting-Yi Hou, Fang-Yu Cheng & Jin-Siang Shaw. (2022) Prediction of Cognitive Degeneration in Parkinson’s Disease Patients Using a Machine Learning Method. Brain Sciences 12:8, pages 1048.
Crossref
Crossref
Charles F. Murchison, Byron C. Jaeger, Jeff M. Szychowski, Gary R. Cutter, Erik D. Roberson & Richard E. Kennedy. (2022) Influence of Subject-Specific Effects in Longitudinal Modelling of Cognitive Decline in Alzheimer’s Disease. Journal of Alzheimer's Disease 87:1, pages 489-501.
Crossref
Crossref
Jayeeta Rajagopalan, Faheem Arshad, Priya Treesa Thomas, Feba Varghese, Saadiya Hurzuk, Rakshith Maneshwar Hoskeri, Renuka Bavikatti Ramappa, Vasundharaa S. Nair, Avanthi Paplikar, Shailaja Mekala, Tejaswini S. Manae, Deepa Boralingana Palya Ramanna, Gurrapu Rakesh, Patel Vishal Ganeshbhai, Shah Rutul Dhiren, Shashidhar Komaravolu, Chandrasekhar Kammammettu, Girish N. Rao & Suvarna Alladi. (2022) Cognition, Behavior, and Caregiver Stress in Dementia during the COVID-19 Pandemic: An Indian Perspective. Dementia and Geriatric Cognitive Disorders 51:1, pages 90-100.
Crossref
Crossref
Edmond Teng, Paul T. Manser, Sandra Sanabria Bohorquez, Kristin R. Wildsmith, Karen Pickthorn, Suzanne L. Baker, Michael Ward, Geoffrey A. Kerchner & Robby M. Weimer. (2021) Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease. Alzheimer's Research & Therapy 13:1.
Crossref
Crossref
Shawn Kile, William Au, Carol Parise, Kimberley Rose, Tammy Donnel, Andrea Hankins, Yvonne Au, Matthew Chan & Azad Ghassemi. (2021) Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease. BMC Neuroscience 22:1.
Crossref
Crossref
James Howlett, Steven M. Hill, Craig W. Ritchie & Brian D. M. Tom. (2021) Disease Modelling of Cognitive Outcomes and Biomarkers in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort. Frontiers in Big Data 4.
Crossref
Crossref
Muhammed Niyas K. P.Thiyagarajan P.. (2021) Alzheimer's classification using dynamic ensemble of classifiers selection algorithms: A performance analysis. Biomedical Signal Processing and Control 68, pages 102729.
Crossref
Crossref
Tatiana Karelina, Stepan Lerner, Alexandr Stepanov, Mark Meerson & Oleg Demin. (2021) Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer’s Disease Platform. CPT: Pharmacometrics & Systems Pharmacology 10:6, pages 543-550.
Crossref
Crossref
Jinhyeong Bae, Jane Stocks, Ashley Heywood, Youngmoon Jung, Lisanne Jenkins, Virginia Hill, Aggelos Katsaggelos, Karteek Popuri, Howie Rosen, M. Faisal Beg & Lei Wang. (2021) Transfer learning for predicting conversion from mild cognitive impairment to dementia of Alzheimer's type based on a three-dimensional convolutional neural network. Neurobiology of Aging 99, pages 53-64.
Crossref
Crossref
Warren Barker, Carlos Quinonez, Maria T. Greig, Raquel Behar, Cesar Chirinos, Rosemarie A. Rodriguez, Monica Rosselli, Miriam J. Rodriguez, Rosie Curiel Cid, Tatjana Rundek, Karen McFarland, Kevin Hanson, Glenn Smith, Steven DeKosky, David Vaillancourt, Malek Adjouadi, Michael Marsiske, Nilufer Ertekin-Taner, Todd Golde, David A. Loewenstein & Ranjan Duara. (2021) Utility of Plasma Neurofilament Light in the 1Florida Alzheimer’s Disease Research Center (ADRC). Journal of Alzheimer's Disease 79:1, pages 59-70.
Crossref
Crossref
Antonio Di Meco & Robert Vassar. 2021. Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Part B. Molecular Biology of Neurodegenerative Diseases: Visions for the Future, Part B
157
173
.
Hilkka Soininen, Alina Solomon, Pieter Jelle Visser, Suzanne B Hendrix, Kaj Blennow, Miia Kivipelto & Tobias Hartmann. (2020) 36‐month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimer's & Dementia 17:1, pages 29-40.
Crossref
Crossref
Ningyuan Zhang, Xijun Zheng, Hongxia Liu, Qingshan Zheng & Lujin Li. (2020) Testing whether the progression of Alzheimer’s disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data. Alzheimer's Research & Therapy 12:1.
Crossref
Crossref
Yan Hai, Xiaoyi Min & Gengsheng Qin. (2020) Bayesian and influence function-based empirical likelihoods for inference of sensitivity in diagnostic tests. Statistical Methods in Medical Research 29:12, pages 3457-3491.
Crossref
Crossref
Helene Karcher, Marina Savelieva, Luyuan Qi, Noemi Hummel, Angelika Caputo, Valery Risson, Gorana Capkun & Alzheimer’s Disease Neuroimaging Initiative. (2020) Modelling Decline in Cognition to Decline in Function in Alzheimer’s Disease. Current Alzheimer Research 17:7, pages 635-657.
Crossref
Crossref
Andrew M Kiselica, Alyssa N Kaser, Troy A Webber, Brent J Small & Jared F Benge. (2020) Development and Preliminary Validation of Standardized Regression-Based Change Scores as Measures of Transitional Cognitive Decline. Archives of Clinical Neuropsychology 35:7, pages 1168-1181.
Crossref
Crossref
Ko Woon Kim, Sook Young Woo, Seonwoo Kim, Hyemin Jang, Yeshin Kim, Soo Hyun Cho, Si Eun Kim, Seung Joo Kim, Byoung-Soo Shin, Hee Jin Kim, Duk L. Na & Sang Won Seo. (2020) Disease progression modeling of Alzheimer’s disease according to education level. Scientific Reports 10:1.
Crossref
Crossref
Antoine R. Trammell, Darius J. McDaniel, Malik Obideen, Maureen Okafor, Tiffany L. Thomas, Felicia C. Goldstein, Leslie M. Shaw & Ihab M. Hajjar. (2020) Perceived Stress is Associated with Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in African Americans with Mild Cognitive Impairment. Journal of Alzheimer's Disease 77:2, pages 843-853.
Crossref
Crossref
Alice Hahn, Young Ju Kim, Hee Jin Kim, Hyemin Jang, Hanna Cho, Seong Hye Choi, Byeong C. Kim, Kyung Won Park, Duk L. Na, Juhee Chin & Sang Won Seo. (2020) The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s disease. Scientific Reports 10:1.
Crossref
Crossref
Manuel Fuentes, Arne Klostermann, Luca Kleineidam, Chris Bauer, Johannes Schuchhardt, Wolfgang Maier, Frank Jessen, Lutz Frölich, Jens Wiltfang, Johannes Kornhuber, Stefan Klöppel, Vera Schieting, Stefan J. Teipel, Michael Wagner & Oliver Peters. (2020) Identification of a Cascade of Changes in Activities of Daily Living Preceding Short-Term Clinical Deterioration in Mild Alzheimer’s Disease Dementia via Lead-Lag Analysis. Journal of Alzheimer's Disease 76:3, pages 1005-1015.
Crossref
Crossref
Sarah J. Banks, Yuqi Qiu, Chun Chieh Fan, Anders M. Dale, Jingjing Zou, Brianna Askew & Howard H. Feldman. (2020) Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures. Alzheimer's & Dementia: Translational Research & Clinical Interventions 6:1.
Crossref
Crossref
Hilkka Liedes, Jyrki Lötjönen, Juha M. Kortelainen, Gerald Novak, Mark van Gils & Mark Forrest Gordon. (2019) Multivariate Prediction of Hippocampal Atrophy in Alzheimer’s Disease. Journal of Alzheimer's Disease 68:4, pages 1453-1468.
Crossref
Crossref
Telma Pereira, Francisco L. Ferreira, Sandra Cardoso, Dina Silva, Alexandre de Mendonça, Manuela Guerreiro & Sara C. Madeira. (2018) Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer’s disease: a feature selection ensemble combining stability and predictability. BMC Medical Informatics and Decision Making 18:1.
Crossref
Crossref
Leslie M. Shaw, Jalayne Arias, Kaj Blennow, Douglas Galasko, Jose Luis Molinuevo, Stephen Salloway, Suzanne Schindler, Maria C. Carrillo, James A. Hendrix, April Ross, Judit Illes, Courtney Ramus & Sheila Fifer. (2018) Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. Alzheimer's & Dementia 14:11, pages 1505-1521.
Crossref
Crossref
Telma Pereira, Luís Lemos, Sandra Cardoso, Dina Silva, Ana Rodrigues, Isabel Santana, Alexandre de Mendonça, Manuela Guerreiro & Sara C. Madeira. (2017) Predicting progression of mild cognitive impairment to dementia using neuropsychological data: a supervised learning approach using time windows. BMC Medical Informatics and Decision Making 17:1.
Crossref
Crossref
Andrea P.V. Lima, Raphael Castilhos & Marcia L.F. Chaves. (2017) The Use of the Clinical Dementia Rating Scale Sum of Boxes Scores in Detecting and Staging Cognitive Impairment/Dementia in Brazilian Patients With Low Educational Attainment. Alzheimer Disease & Associated Disorders 31:4, pages 322-327.
Crossref
Crossref
C.A. Budgeon, K. Murray, B.A. Turlach, S. Baker, V.L. Villemagne & S.C. Burnham. (2017) Constructing longitudinal disease progression curves using sparse, short-term individual data with an application to Alzheimer's disease. Statistics in Medicine 36:17, pages 2720-2734.
Crossref
Crossref
Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A. Beckett, Nigel J. Cairns, Robert C. Green, Danielle Harvey, Clifford R. JackJr.Jr., William Jagust, John C. Morris, Ronald C. Petersen, Andrew J. Saykin, Leslie M. Shaw, Arthur W. Toga & John Q. Trojanowski. (2017) Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. Alzheimer's & Dementia 13:4.
Crossref
Crossref
Shawn Kile, William Au, Carol Parise, Kimberley Rose, Tammy Donnel, Andrea Hankins, Matthew Chan & Azad Ghassemi. (2017) IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia. Journal of Neurology, Neurosurgery & Psychiatry 88:2, pages 106-112.
Crossref
Crossref
Sarah F. Cook & Robert R. Bies. (2016) Disease Progression Modeling: Key Concepts and Recent Developments. Current Pharmacology Reports 2:5, pages 221-230.
Crossref
Crossref
Mahesh N. Samtani, Steven X. Xu, Alberto Russu, Omoniyi J. Adedokun, Ming Lu, Kaori Ito, Brian Corrigan, Sangeeta Raje, H. Robert Brashear, Scot Styren & Chuanpu Hu. (2015) Alzheimer's disease assessment scale-cognitive 11-item progression model in mild-to-moderate Alzheimer's disease trials of bapineuzumab. Alzheimer's & Dementia: Translational Research & Clinical Interventions 1:3, pages 157-169.
Crossref
Crossref
Steven X. Xu, Mahesh N. Samtani, Alberto Russu, Omoniyi J. Adedokun, Ming Lu, Kaori Ito, Brian Corrigan, Sangeeta Raje, H. Robert Brashear, Scot Styren & Chuanpu Hu. (2015) Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials. Alzheimer's & Dementia: Translational Research & Clinical Interventions 1:2, pages 141-149.
Crossref
Crossref